Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.

Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R.

BMJ. 2019 Apr 10;365:l1204. doi: 10.1136/bmj.l1204.

2.
3.

The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.

Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y.

Clin Interv Aging. 2019 Feb 20;14:399-406. doi: 10.2147/CIA.S192435. eCollection 2019.

4.

Why Odds Ratios Can Be Tricky Statistics: The Case of Finasteride, Dutasteride, and Sexual Dysfunction.

Andrade C.

J Clin Psychiatry. 2018 Nov 27;79(6). pii: 18f12641. doi: 10.4088/JCP.18f12641.

PMID:
30549493
5.

Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.

Coskuner ER, Ozkan B, Culha MG.

Sex Med Rev. 2019 Apr;7(2):277-282. doi: 10.1016/j.sxmr.2018.07.003. Epub 2018 Oct 6. Review.

PMID:
30301703
6.

Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.

Lee S, Lee YB, Choe SJ, Lee WS.

Acta Derm Venereol. 2019 Jan 1;99(1):12-17. doi: 10.2340/00015555-3035.

7.

Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.

Haque N, Masumori N, Sakamoto S, Ye Z, Yoon SJ, Kuo HC, Brotherton B, Wilson T, Muganurmath C, McLaughlin M, Manyak M.

Int J Urol. 2018 Nov;25(11):944-951. doi: 10.1111/iju.13785. Epub 2018 Sep 9.

PMID:
30198102
8.

Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results.

Traish AM, Krakowsky Y, Doros G, Morgentaler A.

Sex Med Rev. 2019 Jan;7(1):95-114. doi: 10.1016/j.sxmr.2018.06.002. Epub 2018 Aug 8.

PMID:
30098986
9.

The effect of dutasteride on microscopic and macroscopic changes of testosterone replacement treatment on prostate tissue.

Diri MA, Diri B, Yildiz L, Büyükalpelli R.

Andrologia. 2018 Dec;50(10):e13110. doi: 10.1111/and.13110. Epub 2018 Jul 19.

PMID:
30024036
10.

The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.

Said MA, Mehta A.

Curr Urol Rep. 2018 Jun 16;19(8):65. doi: 10.1007/s11934-018-0814-z. Review.

PMID:
29909472
11.

The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.

Da Silva MHA, Costa WS, B Sampaio FJ, De Souza DB.

Asian J Androl. 2018 Sep-Oct;20(5):505-510. doi: 10.4103/aja.aja_28_18.

12.

Effect of Dose and 5α-Reductase Inhibition on the Circulating Testosterone Metabolite Profile of Men Administered Oral Testosterone.

Basit A, Amory JK, Prasad B.

Clin Transl Sci. 2018 Sep;11(5):513-522. doi: 10.1111/cts.12569. Epub 2018 Jun 19.

13.

Solid dispersion of dutasteride using the solvent evaporation method: Approaches to improve dissolution rate and oral bioavailability in rats.

Choi JS, Lee SE, Jang WS, Byeon JC, Park JS.

Mater Sci Eng C Mater Biol Appl. 2018 Sep 1;90:387-396. doi: 10.1016/j.msec.2018.04.074. Epub 2018 Apr 30.

PMID:
29853105
14.

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.

Antoniou T, Macdonald EM, Yao Z, Gomes T, Tadrous M, Ho JM, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network.

BMC Musculoskelet Disord. 2018 May 22;19(1):160. doi: 10.1186/s12891-018-2076-9.

15.

Limited influence of dutasteride on individual prostate-specific antigen variability in men with clinical benign prostatic hyperplasia.

Takeshita H, Kawakami S, Kagawa M, Yano A, Okada Y, Morozumi M.

Int J Urol. 2018 Jun;25(6):633-634. doi: 10.1111/iju.13557. Epub 2018 Apr 25. No abstract available.

16.

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia.

Tsai TF, Choi GS, Kim BJ, Kim MB, Ng CF, Kochhar P, Jasper S, Brotherton B, Orban B, Lulic Z.

J Dermatol. 2018 Jul;45(7):799-804. doi: 10.1111/1346-8138.14329. Epub 2018 Apr 18.

17.

[Combination drug therapy in patients with BPH].

Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA.

Urologiia. 2018 Mar;(1):101-105. Russian.

PMID:
29634142
18.

Change of the 5α/5β ratio of urinary steroid metabolites in benign prostatic hyperplasia patients treated with dutasteride.

Maeda T, Kikuchi E, Hasegawa M, Homma K, Yasumizu Y, Hattori S, Kosaka T, Shinoda K, Miyajima A, Oya M.

Clin Biochem. 2018 May;55:36-41. doi: 10.1016/j.clinbiochem.2018.03.021. Epub 2018 Mar 31.

PMID:
29608891
19.

Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.

Fertig RM, Gamret AC, Darwin E, Gaudi S.

Dermatol Online J. 2017 Nov 11;23(11). pii: 13030/qt24k8q743. Review.

20.

Influence of antifertility agents Dutasteride and Nifedipine on CatSper gene level in epididymis during sperm maturation in BALB/c mice.

Srivastav A, Changkija B, Sharan K, Nagar GK, Bansode FW.

Reproduction. 2018 Apr;155(4):347-359. doi: 10.1530/REP-17-0664. Epub 2018 Feb 6.

PMID:
29434054

Supplemental Content

Loading ...
Support Center